Zhao Rong, Deng Jinglan, Liang Xiaoyan, Zeng Jin, Chen Xiaoyuan, Wang Jing
Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710032, China.
Childs Nerv Syst. 2010 May;26(5):669-74. doi: 10.1007/s00381-009-1025-1. Epub 2009 Nov 11.
The aim of the study was to evaluate the effect of phosphorus-32 colloid ([(32)P]) intracavitary irradiation on the treatment of patients with cystic craniopharyngiomas.
Twenty patients with predominantly cystic craniopharyngiomas were admitted from 1981 to 2006. Eleven patients had [(32)P] intracavitary irradiation by stereotactic injection or Ommaya cyst instillation as the primary treatment, and the remaining nine had the same internal irradiation as an adjuvant treatment after tumor resection. A calculated irradiation dose of 400 approximately 500 Gy per once was delivered to the cyst wall.
The patients were followed up ranging from 36 to 336 months; no operative morbidity or mortality was found from [(32)P] intracavitary irradiation. Fourteen patients (70%) had tumor progression and required further two to four times intracavitary irradiation. All 20 cases achieved tumor shrinkage or stabilization with effective outcome 3-6 months after the last [(32)P] therapy. For patients with cystic craniopharyngioma, [(32)P] administration by stereotactic injection or Ommaya cyst instillation is a safe and helpful option, which could improve the life quality, prolong the life span, and enhance the survival rate of cystic craniopharyngioma patients.
本研究旨在评估32磷胶体([32P])腔内照射治疗囊性颅咽管瘤患者的效果。
1981年至2006年收治20例以囊性颅咽管瘤为主的患者。11例患者以立体定向注射或Ommaya囊内滴注[32P]腔内照射作为主要治疗方法,其余9例在肿瘤切除后将相同的内照射作为辅助治疗。每次向囊壁给予计算剂量约400至500 Gy的照射。
患者随访36至336个月;[32P]腔内照射未发现手术相关的发病率或死亡率。14例患者(70%)出现肿瘤进展,需要进一步进行两到四次腔内照射。所有20例患者在最后一次[32P]治疗后3至6个月均实现肿瘤缩小或稳定,疗效显著。对于囊性颅咽管瘤患者,立体定向注射或Ommaya囊内滴注[32P]是一种安全且有效的选择,可改善生活质量,延长寿命,并提高囊性颅咽管瘤患者的生存率。